trial

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

NCTId NCT02392468
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 61 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2017-08-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
61 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2015-04-15
Primary completion
2017-08-03
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
BI 409306 25 mgBI 409306 50 mg

Sponsors

Boehringer IngelheimLead Sponsor

Sites

3 total
La Jolla, United StatesEatontown, United StatesAustin, United States

Facts & assertions

4 sourced
Enrollment
61
Phase
PHASE1
Primary Completion Date
2017-08-03
Status
COMPLETED
relationships
The graph out of here
drug
BI 409306 25 mg
drug
BI 409306 50 mg
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Alzheimer Disease
indication
Schizophrenia
indication